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ABSTRACT
DNA methylation, an essential regulator of transcrip-
tion and chromatin structure, is established and
maintained by the coordinated action of three DNA
methyltransferases: DNMT1, DNMT3A and DNMT3B,
and the inactive accessory factor DNMT3L.
Disruptions in DNMT3B function are linked to car-
cinogenesis and genetic disease. DNMT3B is also
highly alternatively spliced in a tissue- and disease-
specific manner. The impact of intra-DNMT3 inter-
actions and alternative splicing on the function
of DNMT3 family members remains unclear. In the
present work, we focused on DNMT3B. Using a
panel of in vitro assays, we examined the conse-
quences of DNMT3B splicing and mutations on its
ability to bind DNA, interact with itself and other
DNMT3’s, and methylate DNA. Our results show
that, while the C-terminal catalytic domain is
critical for most DNMT3B functions, parts of the
N-terminal region, including the PWWP domain, are
also important. Alternative splicing and domain dele-
tions also influence DNMT3B’s cellular localization.
Furthermore, our data reveal the existence of exten-
sive DNMT3B self-interactions that differentially
impact on its activity. Finally, we show that catalyt-
ically inactive isoforms of DNMT3B are capable of
modulating the activity of DNMT3A–DNMT3L com-
plexes. Our studies therefore suggest that seemingly
‘inactive’ DNMT3B isoforms may influence genomic
methylation patterns in vivo.
INTRODUCTION
Genome-wide patterns of DNA methylation in mammals
are established and maintained by a family of three
enzymatically active DNA methyltransferases: DNMT1,
DNMT3A and DNMT3B, and a fourth catalytically
inactive co-factor, DNMT3L. DNMT3L possesses hom-
ology to and stimulates the activity of DNMT3A and
DNMT3B. DNMT3L also ‘directs’ DNA methylation to
genomic regions lacking histone H3, lysine 4 (H3K4)
trimethylation, a mark associated with transcriptional
activity (1,2). DNMT3A, DNMT3B and DNMT3L exist
in a complex in pluripotent cells that interacts with the
core histones (2,3). DNMT1 is traditionally regarded as
the DNMT specialized to carry out maintenance methyla-
tion following replication, while DNMT3A/DNMT3B are
regarded as the de novo enzymes, critical for establishing
new DNA methylation patterns during embryonic and
germ line development (4). While the exact genomic
targets of each DNA methyltransferase have not been sys-
tematically deﬁned, there appear to be both overlapping
and distinct targets of each DNMT. For example, murine
knockout studies revealed a particularly critical role for
Dnmt3b in methylating pericentromeric regions. While
Dnmt1 was also necessary for methylation of perice-
ntromeric domains, Dnmt3a activity was not (5). In
contrast, Dnmt3a and its cofactor Dnmt3L (but not
Dnmt3b1), are critical for establishment of maternal
methylation imprints during oogenesis (4). Exactly how
DNMT3A, DNMT3B and DNMT3L interact and collab-
orate to methylate the genome remains unknown. Since
DNMT3L expression is largely conﬁned to certain devel-
opmental periods or germ cell compartments, mechanisms
of DNMT3L-independent targeting of DNMT3A and
DNMT3B must also exist.
Proper patterns of DNA methylation are essential not
only for mammalian embryonic development, but also for
normal cellular homeostasis once development is complete.
All cancer cells display profound disruptions in DNA
methylation patterns in the form of a global reduction in
DNA methylation, primarily affecting repetitive DNA se-
quences, and at the same time, region-speciﬁc hyper-
methylation events at normally unmethylated CpG island
promoter regions. Repetitive element hypomethylation con-
tributes to genomic instability while CpG island
hypermethylation leads to heritable long-term silencing
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and DNA repair (6,7). Overexpression of Dnmt3b, but not
Dnmt3a, in the Apc
Min/+ murine colon cancer model
system resulted in increased tumor number, micro-
adenoma size and incidence of tumor suppressor gene
hypermethylation events (8) underscoring the importance
of properly regulated DNMT levels to cellular growth
control. Disruption of DNA methylation patterns during
human development also has profound consequences.
Approximately two-thirds of immunodeﬁciency, centro-
mere instability, facial anomalies (ICF) syndrome
patients have germ line mutations in the DNMT3B gene
that are thought to result in at least partial loss of one or
more of DNMT3B’s functions. ICF syndrome patients
display variable defects in B and T cell function, develop-
mental abnormalities, mental retardation and loss of
DNA methylation at pericentromeric and centromeric
regions (satellite 2/satellite 3 repeats and alpha satellite,
respectively), non-satellite repeats, single copy autosomal
genes and genes on the inactive X chromosome (6,9–12).
While several studies have shown that ICF syndrome-
associated DNMT3B mutations reduce its catalytic
activity and/or its ability to interact with DNMT3L
(13,14), much remains unknown as to how partial loss
of DNMT3B function leads to the unusual and cell
type-speciﬁc phenotypes characteristic of ICF patients.
In addition to the important roles for DNMT3B in de-
velopment and carcinogenesis, it stands out among DNA
methyltransferases in the number of alternatively spliced
isoforms derived from the DNMT3B locus (>40) (15,16).
Many alternatively spliced forms of DNMT3B are ex-
pressed in a tissue and/or developmental stage-speciﬁc
manner, such as DNMT3B4/DNMT3B5 in testis (17),
and DNMT3B35, which is associated with pluripo-
tency (18). In tumor cells, normally occurring isoforms,
such as DNMT3B4 in hepatocellular carcinoma and
DNMT3B35 in multiple tumor types, become aberrantly
overexpressed and contribute to pericentromeric repeat
demethylation and genomic instability (18,19). Still other
DNMT3B isoforms appear to be largely tumor speciﬁc.
Ectopic expression of DNMT3B7, the most widely ex-
pressed DNMT3B isoform speciﬁcally linked to cancer,
creates instability in DNA methylation patterns (both
hypo- and hypermethylation events) in cell lines and
promotes tumorigenesis in vivo in an Em-Myc transgenic
mouse lymphoma model (15,20). Interestingly, most of the
DNMT3B alternative splicing events, whether normal
(e.g. DNMT3B3) or tumor associated (e.g. DNMT3B7),
result in isoforms lacking some or all of the C-terminal
catalytic domain and are inactive (DNMT3B3) or pre-
dicted to be inactive (15,21). Exactly how these isoforms
inﬂuence other active co-expressed forms of DNMT3B,
DNMT3A or DNMT3L remains largely unknown;
however, the observation that improper expression of
DNMT3B7 results in developmental defects and enhances
tumorigenesis (20), demonstrates that regulation of
DNMT3B splicing is critically important.
In the present work, we were interested in deﬁning the
domains of DNMT3B that are important for its function
(here referring to its ability to bind and methylate DNA, and
interact with other DNMT3 family members/splice variants),
a n da l s oi nd e t e r m i n i n gh o wt h er e p o r t e dD N M T 3 B –
DNMT3L and DNMT3B–DNMT3A interactions affect
these functions. DNMT3B exists in a complex with
DNMT3A and DNMT3L and it interacts with itself
(2,3,14,20,22–24). One of the most widely expressed splice
variants of DNMT3B (DNMT3B3) is catalytically inactive
yet co-expressed in cells with other active DNMT3 isoforms.
The full extent and functional consequences of intra-
DNMT3 interactions remains unclear. Since DNMT3A
has been more extensively studied in this context than
DNMT3B, we focused our studies on DNMT3B. We ex-
pressed and puriﬁed a panel of DNMT3B splice variants
(human and murine), DNMT3B mutants in which regions
of the N- and C-terminal domains were deleted, and
ICF-syndrome-associated DNMT3B point mutations. All
DNMT3B isoforms were tested for their ability to bind
DNA and to interact with DNMT3L in vitro. Functional
studies included analysis of DNA methylation patterns using
three independent assays based on: methylation-sensitive re-
striction enzyme digestion, bisulﬁte genomic sequencing
(BGS) and bisulﬁte pyrosequencing. We also examined the
effect of different DNMT3B isoforms on the activity of
DNMT3A–DNMT3L complexes as they would be expected
t oo c c u ri nan a t i v ec o m p l e xi nE Sc e l l s( 2 ) ,a n do nt h e i r
cellular localization properties and ability to co-localize with
other Dnmt3s. Our in vitro data reveal the existence of ex-
tensive interactions among DNMT3 family members that
are capable of modulating a number of their func-
tional properties. In addition, our results demonstrate that
DNMT3B isoforms lacking activity, because of alternative
splicing or mutation, are capable of altering the activity
of complexes containing enzymatically active DNMT3
isoforms, suggesting that they contribute to regulating
genomic methylation patterns in vivo.
MATERIALS AND METHODS
Electrophoretic mobility shift assay
Recombinant proteins (preparation described in the
Supplementary Data) were used to analyze protein–
DNA interactions with a satellite 2 DNA probe and
quantitated as described previously (18). Brieﬂy, bands
corresponding to bound and unbound probe were
quantitated using Quantity One 4.6.1 software (BioRad)
to calculate the sum of the intensity of the bands in each
lane. The percent shift curves were ﬁt and KD values were
derived using the three parameter Hill equation [y=ax
b/
(c
b+x
b)] in Sigma Plot 8.0. All electrophoretic mobility
shift assays (EMSAs) were repeated at least twice. Most
EMSA reactions were performed using recombinant
DNMTs in the 0–700nM range. Proteins or protein
mixtures displaying particularly high DNA binding
afﬁnity were repeated using a 0–200nM concentration
range (in 20nM increments). Linear to saturated binding
in these protein concentration ranges was determined em-
pirically in early experiments (not shown). When proteins
were combined, they were used in equimolar amounts.
Statistical signiﬁcance was determined using a two-sample
t-test (NCSS 2001).
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Protein–protein interactions were examined using puriﬁed
recombinant GST-tagged Dnmt3L, Dnmt3b1-C-terminal
domain (CD), Dnmt3b3-CD and GST bound to glutathi-
one sepharose resin (as a negative control, preparation of
proteins is described in the Supplementary Data).
Recombinant 6XHis-tagged proteins (0.05nmol) were
incubated with 2.5–10ml of resin-bound protein (0.6mg)
and, if needed to equalize total resin volume, BSA
blocked empty resin, in either low salt (100mM KCl) or
high salt (150mM KCl) pull down buffer [25 mM HEPES
(pH 7.9), 12.5mM MgCl2, l00 or 150mM KCl, 10%
glycerol, 0.1% NP-40] for 1.5h. Beads were washed
4  for 10min each. After washing, beads were mixed
with an equal volume of 2  protein loading dye and reso-
lved on an 8% SDS–PAGE gel. Proteins were transferred
overnight to PVDF membrane. Protein interactions with
GST fusion proteins were detected by western blotting
with anti-6XHis antibody [His-probe (H-15): SC-803,
Santa Cruz or monoclonal anti-His: G020, ABM, 1:1000
dilution] as described previously (18). Films with pull
down and input were scanned and the composite images
shown generated without further computerized image
adjustment (e.g. alterations in contrast, brightness, etc.).
DNA methyltransferase activity assays
Activity assay conditions, adapted from Takeshima et al.
(25), were 20mM Tris (pH 7.4), 5mM EDTA, 25mM
NaCl, 10% glycerol, 200mM DTT, 80mM S-adenosyl-L-
methionine (SAM, New England Biolabs) and 1.5mg
pSL301 plasmid containing the SAT2 sequence. The
reaction mixture was incubated at 37 C for 7h, with
fresh SAM added after the ﬁrst 4h. For reactions
comparing enzyme activity with and without Dnmt3L,
0.15nmol of each puriﬁed methyltransferase was mixed
in equimolar concentrations. For reactions combining
Dnmt3b’s with Dnmt3a and Dnmt3L, 0.06nmol of each
puriﬁed methyltransferase was used. A negative control
(an active methyltransferase but no SAM) was also
included in all reactions. For restriction enzyme digestion
analysis, 0.5mg of plasmid from the assay mixture was
removed and digested with 400mg/ml proteinase K at
55 C for 10min. The digest was extracted once with phe-
nol:chloroform:iso-amyl alcohol and ethanol precipitated.
The precipitated DNA was digested with 5U of HpaII
overnight and analyzed on a 1.5% agarose gel stained
with ethidium bromide. Gels were visualized using a
Bio-Rad gel documentation system and bands were
quantitated using Quantity One software (v4.6.1,
Bio-Rad). The relative quantity of higher molecular
weight bands that resulted from methylation-mediated in-
hibition of HpaII digestion was calculated as a percentage
using the sum of the intensity of the bands in each lane.
BGS and pyrosequencing
Following the methyltransferase activity assay, 0.5mgo f
plasmid was digested with 10U of PvuII (to linearize)
in preparation for bisulﬁte modiﬁcation. Bisulﬁte modi-
ﬁcation was performed essentially as described (12).
An additional denaturation step, heating at 95 C for
10min, was included prior to addition of sodium hy-
droxide. Modiﬁed plasmid DNA was then used as a
template for BGS and pyrosequencing. BGS PCR
products were gel puriﬁed using the Qiaex II Gel
Extraction Kit (Qiagen). PCR products were then cloned
using the TOPO TA Cloning Kit (Invitrogen). At least 10
clones were sequenced for each PCR product using the
M13 reverse primer. All sequencing was completed by
the Interdisciplinary Center for Biotechnology Research
at the University of Florida. Sequence data was
analyzed and ﬁgures generated using the web-based
Quantiﬁcation Tool for Methylation Analysis (QUMA)
software (26). Processivity analyses were completed by
calculating the processivity indices using the BGS data
as in ref. (27) where an index of 1 indicates that all
CpGs in the clone are methylated and 0 indicates that
no contiguous CpGs are methylated. Only clones exhibit-
ing methylated CpG sites could be scored. Signiﬁcance
was calculated using the Wilcoxon rank-sum test (NCSS,
2001). For pyrosequencing, the forward primers were the
same as for BGS and the reverse primers were biotinylated
at the 50-end (Supplementary Table S1). Pyrosequencing
PCR products (10–15ml) were used with PyroMark Gold
Q96 Reagents on a PyroMark MD Pyrosequencer
(Qiagen) following the manufacturer’s protocol and as
described previously (28). Background was subtracted
using the inactive/negative controls, which were included
in all pyrosequencing runs.
Transfections and microscopy
HEK 293T cells (American Type Culture Collection) were
cultured in McCoy’s-5A media supplemented with 10%
heat inactivated fetal bovine serum and 2mM L-glutam-
ine. Cells were plated at 10
5/ml on 25mm diameter cover
slips in six-well tissue culture dishes. After 48h, cells were
transfected with 2mg of each expression construct using
Lipofectamine 2000 transfection reagent according to the
manufacturer’s protocol (Invitrogen). Twenty-four hours
after transfection, cells were ﬁxed in 2% paraform-
aldehyde in 1  PBS. DNA was counterstained with
1mg/ml bisBenzimide H33342 trihydrochloride (Sigma-
Aldrich) in 1  PBS and coverslips were mounted onto
glass slides with Fluoromount-G (Southern Biotech).
Cells were visualized and photographed using a Zeiss
LSM 510 META confocal microscope.
RESULTS
In vitro systems for studying Dnmt3b function
The domains responsible for the Dnmt3a–Dnmt3a and
Dnmt3a–Dnmt3L interactions, as well as Dnmt3a enzym-
atic activity, have been much more extensively studied
than those of Dnmt3b (1,13,23,29), likely because
Dnmt3b displays the lowest catalytic activity among
DNMT family members in vitro. In addition, an ever
growing number of Dnmt3b splice variants are being
identiﬁed (15,18) and their effect on Dnmt3b in isolation
and on other Dnmt3b variants, Dnmt3a and Dnmt3L, are
largely unknown. To begin to address these issues we
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which we deleted regions of the N- and C-terminal domain
[including the known PWWP motif that contributes to
Dnmt3b DNA and heterochromatin binding (30,31), and
the PHD domain, which may mediate interactions between
Dnmt3b and other chromatin modiﬁers (32)], and a panel
of ICF syndrome-associated Dnmt3b mutants that were
expressed and puriﬁed as hexahistidine-tagged (6XHis)
fusions from baculovirus infection of Sf9 insect cells
or as glutathione-S-transferase (GST) fusion proteins
from Escherichia coli (Figure 1A and B). To study the
functional effects of these mutations on Dnmt3b, we
employed a panel of assays to measure protein–DNA
interaction (EMSA), enzymatic activity (using three
assays: methylation-sensitive restriction enzyme digestion,
BGS and bisulﬁte pyrosequencing), and protein–protein
interactions using GST pull downs (Figure 1C). The sub-
strate used for the DNA binding and enzymatic activity
assays is a plasmid containing a 392bp fragment of human
satellite 2 (SAT2) repeat derived from chromosome 1.
Methylation of the entire plasmid (3656bp) was assessed
by digestion with the CpG methylation-sensitive restric-
tion enzyme HpaII and smaller regions of the plasmid
backbone and SAT2 insert were analyzed at high reso-
lution using BGS and/or pyrosequencing (Figure 1D).
SAT2 is a well established, CpG-rich, native DNMT3B
target sequence in vivo (5,24). A comparably CpG-rich
region of the plasmid backbone was used as a compari-
son to SAT2 for most assays to determine if particular
effects were sequence speciﬁc. Effects were monitored
using in vitro assays so that all aspects of the reactions
(proteins, substrates, conditions and stoichiometry)
could be experimentally deﬁned and easily manipulated.
Effect of Dnmt3b alternative splicing on protein–DNA
interactions, interaction with Dnmt3L, and
enzyme activity
To begin to examine the functional consequences of
Dnmt3b alternative splicing, we expressed and puriﬁed
murine and human Dnmt3b1, the full-length enzyme ex-
pressed largely in ES cells (16), murine Dnmt3b2 and
murine/human Dnmt3b3. Dnmt3b3 is among the most
widely expressed Dnmt3b splice variants in somatic cells
(16,17).MurineDnmt3awasusedasareferencetocompare
its properties to those of Dnmt3b using the same panel of
in vitro assays. Effects of alternative splicing on Dnmt3b
DNA binding were assessed by EMSA using a 461-bp
fragment containing human SAT2 (18). Increasing concen-
trations of puriﬁed recombinant Dnmt3 (0–700nM) were
added to a ﬁxed concentration of SAT2 DNA probe,
DNA–protein complexes were resolved on agarose gels
and visualized using SYBR green staining, and binding
afﬁnities determined using the Hill equation, as we have
done previously (18). Representative EMSA gels are
shown in the top portion of Figure 2A. Dnmt3b1 displayed
the highest DNA binding afﬁnity among the isoforms
tested (KD=183nM, Table 1). Exclusion of exon 11
(Dnmt3b2) reduced DNA binding afﬁnity and exclusion
of exons 11, 22 and 23 (Dnmt3b3 isoform) further reduced
binding afﬁnity (KD=293nM). The DNA binding
afﬁnities of human DNMT3B1 and DNMT3B3 (lacking
exons 10, 21 and 22) were almost identical to their murine
homologs. The binding afﬁnity of Dnmt3a for SAT2 was
the highest of all Dnmt3 isoforms tested (Figure 2A and
Table 1). Quantitation data ﬁt to the Hill equation for
all Dnmt3s is shown in the lower panel of Figure 2A and
all KD values derived from these plots are summarized in
Table 1.
Consequences of alternative splicing on Dnmt3b’s
ability to interact with Dnmt3L were then examined
using GST pull downs. Buffers of low and moderate strin-
gency (deﬁned by KCl concentration) were employed to
obtain an estimate of interaction strength. While all
murine and human Dnmt3b isoforms interacted strongly
with GST-Dnmt3L under lower stringency conditions
(except the 671–859 mutant), the Dnmt3L–Dnmt3b2
and Dnmt3L–Dnmt3b3 interactions were lost under the
moderate stringency pull down conditions (Figure 2B,
Table 1), suggesting that these alternatively spliced
regions contribute to the Dnmt3L–Dnmt3b interaction.
Identical results were obtained with human DNMT3B1
and DNMT3B3. Loading control westerns for both the
6XHis- and GST-tagged proteins, which were set-up in
an identical manner to and western blotted with the pull
downs (lower panels of Figure 2B) demonstrate that
samples are comparably loaded. Using baculovirus/Sf9-
derived 6XHis-tagged Dnmt3L in a pull down reaction
with GST-Dnmt3L, we found no evidence that Dnmt3L
interacts with itself (data not shown). While it is well es-
tablished that Dnmt3L stimulates the activity of Dnmt3a
and Dnmt3b and enhances Dnmt3a cofactor SAM
binding, Dnmt3L did not appear to alter Dnmt3a’s
DNA binding afﬁnity in a previous study (1). When
DNMT3B1 was mixed with GST-Dnmt3L we observed
signiﬁcant enhancement of DNA binding afﬁnity
compared to addition of equivalent amounts of GST
(Figure 2A) demonstrating that, at least for DNMT3B1
and SAT2 under our reaction conditions, Dnmt3L is cap-
able of modulating the DNA binding afﬁnity of
DNMT3B. Dnmt3L alone did not bind SAT2 in the pro-
tein concentration range we employed (data not shown).
DNMT3B3–Dnmt3L complexes did not resolve sufﬁcient-
ly on the EMSA gels preventing us from determining if
Dnmt3L also enhanced the binding of this Dnmt3b splice
variant (data not shown). Effects of Dnmt3b alternative
splicing on its interaction with Dnmt3L are summarized in
Table 1.
We next analyzed the effect of alternative splicing on
Dnmt3b enzymatic activity using three different methods.
In the ﬁrst assay, the 3656bp SAT2-containing plasmid
was used as a substrate for in vitro methylation reactions
(Figure 1D). Following a 7h incubation of enzyme with
DNA and SAM, protein was removed by phenol extrac-
tion/ethanol precipitation and the plasmid DNA was
digested with HpaII, which only cuts the sequence
50-CCGG-30 if the internal cytosine is unmethylated.
While lower resolution, this assay allows for analysis of
a large number of CpG sites over the entire plasmid. As
expected, human and murine Dnmt3b1 and Dnmt3b2
were active on their own, albeit at low levels, and were
stimulated  2–7-fold by the addition of an equimolar
Nucleic Acids Research, 2011,Vol.39, No. 12 4987Figure 1. Assay systems, constructs and DNA templates used to assess Dnmt3b functions in vitro.( A) Schematic representation of Dnmt3b1 and the
splice variants/deletions expressed and puriﬁed for in vitro studies. Critical domains and catalytic motifs are highlighted. SAM interaction sites are
indicated by orange arrows. Numbers represent the amino acids of murine Dnmt3b1. Amino acids listed below represent ICF syndrome-associated
mutations introduced into the murine sequence at homologous positions to human DNMT3B1 (Supplementary Table S2). Amino acids and
red/green bars above Dnmt3b1 represent regions predicted to be important for protein–protein interaction based on Dnmt3a–Dnmt3L structural
studies (29). (B) Representative coomassie blue stained gel showing a subset of the in vitro expressed puriﬁed 6XHis-tagged recombinant proteins
used in this study. (C) Box chart of methodology employed to analyze functional effects of splice variants/deletions/ICF mutations. (D) Plot of CpG
and HpaII sites in the plasmid containing the satellite 2 (SAT2) sequence used as the template DNA for in vitro activity and protein–DNA
interaction assays. CpG sites analyzed by bisulﬁte genomic sequencing (BGS) and pyrosequencing (denoted by thick horizontal lines) are
enlarged and shown below.
4988 Nucleic Acids Research, 2011,Vol.39, No. 12Figure 2. Functional effects of Dnmt3b alternative splicing on protein–DNA binding, interaction with Dnmt3L, and enzyme activity. (A) Top panel:
representative SYBR green stained EMSA gels with increasing amounts of the Dnmt3 proteins indicated (0–700nM). Arrowhead—free probe.
Bottom panels: percent shift quantitated from EMSA gels. Curves were ﬁt using the Hill equation. Left: Dnmt3b’s and Dnmt3a. Right: effect of
Dnmt3L (or GST) on DNMT3B1 binding to DNA. (B) GST pull down analysis of protein–protein interactions between the indicated Dnmt3
Continued
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displayed the highest level of enzymatic activity on its own
and Dnmt3b3 was completely inactive with and without
Dnmt3L.
To examine DNA methylation quantitatively at single
CpG resolution and to determine if site preferences exist,
we used bisulﬁte pyrosequencing. While pyrosequencing is
limited to a relatively small region ( 50bp), it is highly
quantitative, provides single CpG site resolution, and is
amenable to test a large number of reaction conditions
(33). A 49-bp region (with ﬁve CpG sites) of the plasmid
backbone and a 68-bp region (containing seven CpG sites)
of the SAT2 insert were analyzed by pyrosequencing
(Figure 1D). In keeping with the previous analysis, all
Dnmt3 isoforms displaying enzymatic activity in the
HpaII assay also demonstrated activity on the SAT2
insert (Figure 2D) and the plasmid backbone
(Supplementary Figure S1A). Data are presented as the
percent methylation at each CpG site in the analyzed
region (Figure 2D and Supplementary Figure S1A) and
as a total percent methylation averaged across all sites
(Table 1). Interestingly, while Dnmt3L addition stim-
ulated methylation at all sites to some extent ( 3–5-fold
for human/murine Dnmt3b1), there were some marked
differences in the ability of Dnmt3b to methylate certain
CpG sites. For example, CpGs 2, 6 and 7 in the SAT2
pyrosequencing region were less well methylated by
Dnmt3b1 than the remaining CpG sites, and, interest-
ingly, these three sites were among the most highly methyl-
ated by Dnmt3a (Figure 2D). Addition of Dnmt3L
preferentially increased methylation at CpG sites less
preferred by Dnmt3b (or Dnmt3a) alone (Figure 2D,
Supplementary Figure S1A). Dnmt3L-mediated increases
in Dnmt3a and Dnmt3b1 activity on SAT2 were not linear
across each CpG site, but rather exhibited a hyperbolic
correlation as the fold change was greatest at sites of
low methylation and decreased at sites with high methy-
lation (Supplementary Figure S1B). This trend, however,
was not visible with Dnmt3b1 on the plasmid sequence as
the three CpGs with the lowest methylation showed no
increase, or even decreased methylation, when Dnmt3L
was present in the reaction (Supplementary Figure S1B).
While there was a strong correlation between sites methyl-
ated by each active Dnmt3b isoform in the presence of
Dnmt3L (e.g. Dnmt3b1+Dnmt3L versus Dnmt3b2+
Dnmt3L), there was no correlation between CpG sites
methylated by Dnmt3b compared to Dnmt3a (both in the
presence of Dnmt3L), indicating that these two enzymes
have distinct site preferences (Figure 2E, Supplementary
Figure S1B). In addition, while the activity of Dnmt3b2
on its own was lower than that of Dnmt3b1 at all CpG
sites, addition of Dnmt3L increased Dnmt3b2 activity sub-
stantially ( 10–58-fold for SAT2 and plasmid regions)
such that the total level of methylation resulting from the
Dnmt3b2+Dnmt3Lreactionwasalmostthesameasthatin
the Dnmt3b1+Dnmt3L reaction (Figure 2D, Table 1).
Therefore the Dnmt3b2 splice variant does not alter
sequence preference. Although human DNMT3B1 gener-
ally had greater activity than murine Dnmt3b1, the overall
pattern (or preference) of CpG site methylation of the
human and murine enzymes was very similar (Figure 2D
and E, Supplementary Figure S1A and B).
Finally, for many of the catalytically active Dnmt3b
isoforms (3b1/3b2), we analyzed DNA methylation pat-
terns over the entire 531bp SAT2 insert (28 CpG sites)
and a roughly equivalent sized region of the plasmid
backbone (491bp, 30 CpGs) as a comparison, using trad-
itional BGS. Results for the single clone-based analysis
(summarized in Figure 2F, Supplementary Figure S1C
and D and Table 1) are generally very comparable to the
data derived from pyrosequencing. All Dnmt3b constructs
possessed low to moderate activity on their own and were
stimulated by addition of Dnmt3L. As for the pyro-
sequencing experiments, Dnmt3b2 displayed lower activity
than Dnmt3b1 on SAT2, but Dnmt3b2 was stimulated to
a much greater extent by Dnmt3L than Dnmt3b1 was
(Table 1). Results with the plasmid sequence differ to
some extent from SAT2 in that Dnmt3b1 and Dnmt3b2
are more similar in their activity levels, suggesting that
Dnmt3b activity and Dnmt3L stimulation may, to some
extent, be context speciﬁc. By analyzing patterns of DNA
methylation across each clone, we also determined that
humanandmurineDnmt3b1methylatedbothsubstratesin
a processive manner, consistent with an earlier study (13).
Interestingly, addition of Dnmt3L to the reactions signiﬁ-
cantly increased Dnmt3b processivity (Supplementary
Figure S1E). Although Dnmt3b2 showed a similar trend
in processivity, this did not reach signiﬁcance because of
its lower methylation activity. Thus, like Dnmt3a (34),
Dnmt3L acts as a processivity factor for Dnmt3b as
well; increasing Dnmt3b methylation at all CpG sites
to some extent (Supplementary Figure S1B). Finally, we
interrogated our BGS data for the presence of non-CpG
methylation, which was recently shown to be much more
common thanpreviously thought,atleastinstem cells(35).
In vitro methylation reactions revealed the presence of low
Figure 2. Continued
constructs and GST-Dnmt3L. Western blotting with anti-His antibody was used to detect interactions. +: pull down with GST-Dnmt3L, –: pull
down with GST, low and high refer to the 100 and 150mM KCl used in binding reaction/washes, respectively. The 6X-His fusion protein and
GST-fusion protein loading inputs for each reaction are shown below the pull downs to illustrate equal loading. Reactions identical to the pull
downs, without washing, were run along with all pull down reactions and proteins detected by western blotting with antibodies against the 6XHis or
GST tags. Arrowhead—speciﬁc protein, asterisk—non-speciﬁc band. (C) Representative HpaII restriction digests of SAT2-containing plasmid fol-
lowing the methyltransferase activity assay. –, Dnmt3 enzyme alone; +, Dnmt3 and Dnmt3L. Numbers below indicate percentage methylation
quantiﬁed from changes in band patterns resulting from inhibition of HpaII cutting due to methylation. (D) Methylation of individual CpG sites in
SAT2 (Figure 1) by Dnmt3s with and without Dnmt3L analyzed by pyrosequencing. Error bars indicate standard deviation. (E) Linear correlation of
methylation of individual CpGs between Dnmt3b1 with Dnmt3L and the other indicated Dnmt3s with Dnmt3L using SAT2 pyrosequencing data.
Dnmt3b2 and Dnmt3L R: 1, R
2: 1; Dnmt3a and Dnmt3L R: 0.61, R
2: 0.37; DNMT3B1 and Dnmt3L R: 1, R
2:1 .( F) SAT2 BGS results for Dnmt3s
with and without Dnmt3L. Overall percentage methylation is indicated in parentheses. White circles: unmethylated CpG, black circles: methylated
CpG. Each row represents one sequenced clone.
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Nucleic Acids Research, 2011,Vol.39, No. 12 4991but signiﬁcant non-CpG methylation with a preferred
contextofCA>CT>CC(SupplementaryFigure S1F),sup-
porting the notion that the Dnmt30s may be primarily re-
sponsible for non-CpG methylation in vivo in cell types
where they are highly expressed, such as stem cells. Taken
together, our analysis of three common Dnmt3b isoforms
reveals that alternative splicing results in changes in the
ability of Dnmt3b to bind DNA, to interact with
Dnmt3L, and to catalyze DNA methylation.
Effects of Dnmt3b1 domain deletions on enzyme–DNA
interactions, interaction with Dnmt3L, and enzyme
activity
We next analyzed the role of different regions of the Dnmt3b
N- and C-terminal domains in regulating its function. Given
the similar properties of human and murine Dnmt3b1 and
Dnmt3b3 in our previous assays, we performed subsequent
studies using only murine forms of Dnmt3b. The N-terminal
region of Dnmt3b has at least one, relatively non-speciﬁc,
DNA binding domain, the PWWP region (30). In our
assays, the entire Dnmt3b N-terminal domain (amino
acids 1–583) bound to the SAT2 DNA probe with
moderate afﬁnity (KD= 239nM, Figure 3A and Table 1).
Deletion of the extreme N-terminal region of Dnmt3b in the
context of the full-length proteinr e s u l t e di nas m a l li n c r e a s e
in DNA afﬁnity, while deletion of the PHD domain reduced
afﬁnity for SAT2 relative to FL Dnmt3b1. Interestingly, a
smaller fragment of the Dnmt3b1 N-terminus encompass-
ing amino acids 1–433, bound SAT2 with high afﬁnity
(KD=45nM, Supplementary Figure S2A) suggesting the
existence of a strong DNA binding domain in this region.
The relevance of this region in the context of full-length
Dnmt3b1 is unclear but could become important in
C-terminally truncated cancer-speciﬁc splice variants
(15,21). The isolated C-terminal catalytic domain of
Dnmt3b1 also bound DNA, consistent with it retaining
activity, but with greatly reduced afﬁnity (Figure 3A and
Table 1).
Interaction of Dnmt3b deletion mutants with Dnmt3L
was assessed using GST pull down. All deletions and a
Figure 3. Functional effects of Dnmt3b1 domain deletions on enzyme–DNA binding, interaction with Dnmt3L, and enzymatic activity.
(A) Quantiﬁcation of percent shifts from EMSA gels (not shown) as described in Figure 2A using the SAT2 DNA probe. (B) Western blot detection
of protein–protein interactions between Dnmt3b1 deletions and GST-Dnmt3L following GST pull down analysis under low and moderate stringency
conditions (100 and 150mM KCl, respectively). Symbols are as described in Figure 2B. Input (I) represents the loading of each 6X-His fusion bait
protein and is the same for low and high pull downs. (C) Overall methylation of the SAT2 sequence by Dnmt3b1 deletions and the Dnmt3b1 C657A
catalytic mutant with and without Dnmt3L determined using pyrosequencing.
4992 Nucleic Acids Research, 2011,Vol.39, No. 12catalytic site point mutant Dnmt3b1 (C657A) retained
some ability to interact with Dnmt3L, with the exception
of the 671–859 construct. Thus, in the presence of the
N-terminus, sequences between amino acids 584 and 671
(including motif I), appear to negatively impact Dnmt3b–
Dnmt3L interaction. In contrast, a previous study using
the isolated C-terminal domain of Dnmt3b reported that
motif I appeared essential for Dnmt3b–Dnmt3L inter-
action (23). The differing results may be due to our use
of the FL form of Dnmt3b or, alternatively, may indicate
a defect in the folding of our recombinant 671–859
protein. While the C-terminal domain of Dnmt3b is sufﬁ-
cient to interact with Dnmt3L, regions of the N-terminus
also play a role in this interaction since deletion of the
PWWP domain and ﬂanking sequences (e.g. 225–249
mutant) reduced the strength of the Dnmt3b–Dnmt3L
interaction (Figure 3B and Table 1).
Pyrosequencing DNA methylation analysis of SAT2
and plasmid regions revealed that, while the isolated cata-
lytic domain of Dnmt3b1 is active and capable of being
stimulated by Dnmt3L, as reported previously (36), its
activity is greatly reduced compared to the full-length
form (Figure 3C and Supplementary Figure S2B). The
C657A mutant was completely inactive (by both pyro-
sequencing and BGS, Figure 3C and Supplementary
Figure S2B–D), demonstrating the existence of only one
catalytic center in Dnmt3b. Like the interaction between
Dnmt3b and Dnmt3L, the N-terminal region also inﬂu-
enced catalytic activity. For example, deletion of the
PWWP domain and ﬂanking sequences (e.g. 227–429)
dramatically reduced activity, while deletion of the PHD
domain or the extreme N-terminus of Dnmt3b resulted in
more mild changes in activity (Figures 3C, Supplementary
Figure S2B and Table 1). The reduced ability of Dnmt3L
to stimulate the activity of mutants such as 227–429,
particularly on SAT2, is in keeping with their impaired
ability to interact with Dnmt3L (Figure 3B). BGS data
of Dnmt3b1 mutants that retained detectable activity
was consistent with the pyrosequencing data and also re-
vealed that none of the domain deletions altered Dnmt3b’s
CpG site preference in the presence or absence of Dnmt3L
(Supplementary Figure S2C and D). Taken together, these
data reveal that while many of the properties of Dnmt3b
are intrinsic to and maintained in the isolated catalytic
domain, the N-terminal domain clearly inﬂuences these
properties, suggesting that splice variants lacking regions
of the N-terminus may possess altered functions in vivo.
Inﬂuence of ICF syndrome point mutations on Dnmt3b1
protein–DNA interaction, interaction with Dnmt3L, and
enzymatic activity
Although a previous study examined the functional con-
sequences of several ICF-associated Dnmt3b mutations,
the isolated C-terminal domain was used for these experi-
ments (13). Our data show that the N-terminal domain
inﬂuences several properties previously thought to be
linked exclusively to the C-terminus (e.g. Dnmt3L inter-
action). To examine how these point mutations alter
Dnmt3b function in the context of the full-length
protein, eight ICF syndrome patient-derived DNMT3B
mutations were introduced into the homologous positions
of murine Dnmt3b1 [Supplementary Table S2, (14)], ex-
pressed and puriﬁed from baculovirus infected Sf9 cells.
EMSA DNA binding analysis using the SAT2 probe, one
of the sequences invariantly hypomethylated in ICF
syndrome patients (11), revealed that all ICF Dnmt3b mu-
tations mildly to moderately (e.g. R846Q KD=303nM)
reduced DNA binding afﬁnity, although all eight mutants
clearly retain the ability to bind DNA (Figure 4A and
Table 1).
The Dnmt3b–Dnmt3L interaction, assessed using GST
pull downs, showed that, with the exception of the G669S
mutant, all other ICF Dnmt3b mutations caused a reduc-
tion in the strength of the Dnmt3b–Dnmt3L interaction
compared to the WT form (Figure 4B and Table 1). For
example, the V612A mutation immediately adjacent to
conserved motif I interacted only weakly with Dnmt3L
in the low ionic strength buffer conditions. Sequences
adjacent to conserved motif X (e.g. the R829G
mutation) also appear to play an important role in the
Dnmt3b–Dnmt3L interaction (Figure 4B and Table 1).
Our results are, at least qualitatively, similar to those
reported in an earlier study of Dnmt3b–Dnmt3L inter-
actions using a similar panel of mutations in the context
of the isolated C-terminal domain of Dnmt3b in a mam-
malian two-hybrid assay (14), with the exception of the
R829Q mutant. The differences may be attributable to our
use of the full-length form of Dnmt3b1 for all assays.
When levels of enzymatic activity were examined, the
L670T, V732G, A772P and H820R mutations were essen-
tially inactive when tested with the SAT2 and plasmids
sequences in pyrosequencing assays. Less than 1% methy-
lation was detected without Dnmt3L and<2% methyla-
tion was detected in the presence of Dnmt3L for the
L670T, V732G, A772P mutants. While these values may
reﬂect bona ﬁde residual activity in the presence of
Dnmt3L detectable because of the high sensitivity and re-
producibility of the pyrosequencing assays, it is still sufﬁ-
ciently low that its biological signiﬁcance, if any, is
questionable (Figure 4C, Supplementary Figure S3A and
Table 1). Interestingly this low-level activity is only
observed with the SAT2 sequence, not the plasmid. The
R829G and R846Q mutants, despite having reduced DNA
binding afﬁnity and ability to interact with Dnmt3L,
retained a low level of activity alone that was stimulated
by Dnmt3L, on a fold-change basis, to levels comparable
with wild-type Dnmt3b1 (Table 1). We also used the
pyrosequencing data to examine whether ICF syndrome-
associated mutations altered CpG preference of Dnmt3b.
Analysis of the SAT2 and plasmid regions indicated that
all mutations reduced activity proportionally at all CpG
sites rather than exerting an effect on a subset of sites
(Supplementary Figure S4). BGS analysis also conﬁrmed
the pyrosequencing data over the larger SAT2 and
plasmid backbone regions, reinforcing the conclusion
that ICF syndrome-associated point mutations do not
alter the intrinsic CpG site preferences of Dnmt3b
(Figure S3B and C). Curiously, the activity of the
V612A mutant, which displayed impaired but not abol-
ished ability to interact with Dnmt3L, was actually re-
pressed upon addition of Dnmt3L for the SAT2
Nucleic Acids Research, 2011,Vol.39, No. 12 4993sequence (Table 1). Our data are largely in agreement with
those obtained by Gowher et al. (13) who used several of
the same mutations we examined in the context of the
isolated Dnmt3b catalytic domain even though completely
different assays were used to detect methylation. With the
exception of the A772P and R846Q mutants, our results
are also similar to those reported in a later study (14) using
many of the same mutants in the context of full-length
Dnmt3b1 expressed in bacteria. Differences may be attrib-
utable to the use of different buffer conditions and DNA
substrates, or our use of the more sensitive pyro-
sequencing method to assess DNA methylation levels. In
any case, our data clearly support the notion that ICF
syndrome-associated Dnmt3b mutations have diverse
effects on multiple properties of Dnmt3b that likely
contribute to patient phenotypic variability.
Consequences of alternative splicing, domain deletions,
and ICF syndrome-associated point mutations on Dnmt3b
self-interactions
It has become clear from structural studies that not only is
the Dnmt3a–Dnmt3L interaction important for Dnmt3a’s
biological activity, but also the ability of Dnmt3a to
interact with itself and mediate formation of the 3L–3a–
3a–3L heterotetramer proposed to represent the active
form of Dnmt3a in cell types that co-express both
proteins (29). We have shown previously limited evidence
for a Dnmt3b1–Dnmt3b3 interaction using the yeast two
hybrid assay (24), and the DNMT3B7 splice variant was
recently shown to interact with other endogenous Dnmt3b
isoforms by co-immunoprecipitation (20); however,
Dnmt3b–Dnmt3b ‘self’interactions havenot,toourknow-
ledge, been examined rigorously. To investigate this, we
utilized GST pull downs under the same low and moderate
stringency conditions used to study the Dnmt3b–Dnmt3L
interaction. The C-terminal domains of Dnmt3b1 and
Dnmt3b3 were fused to GST and expressed in E. coli as
the ‘bait’. Hexahistidine tagged Dnmt3b constructs,
puriﬁed from baculovirus infected Sf9 cells (the ‘prey’),
were incubated with GST fusions and interactions moni-
tored by western blotting with an antibody directed against
the 6XHis tag. The Dnmt3b1 C-terminus interacted with
full-length Dnmt3b1 and Dnmt3b3 isoforms, but, inter-
estingly, did not interact with Dnmt3b2 (Figure 5A and
Table 1). Results from pull downs using the Dnmt3b3
C-terminus were similar except that all interactions were,
unexpectedly, more robust than for the Dnmt3b1
C-terminus (e.g. the Dnmt3b3 C-terminus interacted with
Dnmt3b2, albeit weakly, under the lower stringency condi-
tions, Figure 5B and Table 1). The Dnmt3b3 C-terminus
Figure 4. Functional effects of ICF syndrome mutations on Dnmt3b1 protein–DNA interactions, interaction with Dnmt3L, and enzymatic activity.
(A) Quantiﬁcation of EMSA gels and Hill plots summarizing the binding of each Dnmt3b1 mutant (0–700nM) to the SAT2 DNA probe.
(B) Representative western blots showing protein–protein interactions of Dnmt3b1 mutants and GST-Dnmt3L by GST pull down as described in
Figures 2B and 3B. (C) Pyrosequencing-based determination of overall percent methylation of the SAT2 sequence by mutant Dnmt3b1 isoforms with
and without Dnmt3L.
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N-terminal domain. This result is consistent with the ob-
servation that DNMT3B7 interacts with other DNMT3B
isoforms (20) as well as with earlier studies where the N-
and C-terminal domains of DNMT1 were shown to
interact (37). Dnmt3a interacted strongly with both the
Dnmt3b1 and Dnmt3b3 C-termini (Table 1). It is also
possible that the interactions we observe are, to some
extent, modulated by which partner is free in solution
(6XHis-tagged) versus bound to a solid support (GST-
tagged). Such effects might, for example, explain differ-
ences in binding afﬁnity between Dnmt3b1 and Dnmt3b3
(compare Figure 5A third panel to Figure 5B ﬁrst panel).
Differences in binding between the Dnmt3b1-CD and the
Dnmt3b3-CD are not attributable to variability in the
amounts of input proteins as these are comparable across
all pull downs (Figure 5C and D).
Our GST pull down experiments using the Dnmt3b
domain deletions revealed that interactions involving the
C-terminus of the Dnmt3b1 isoform were much more
sensitive to deletions within the C-terminal domain, as
would be predicted from the Dnmt3a structure [(29) and
Figure 1]. Deletions within the Dnmt3b1 N-terminus
[e.g. amino acids 1–140 and the PWWP domain],
however, also weakened or abolished interactions with
the Dnmt3b1 C-terminus (Figure 5A and Table 1). In
contrast, the Dnmt3b3 C-terminus interacted moder-
ately to strongly with all domain deletions (Figure 5B
and Table 1). Interestingly, the active site point mutant,
Dnmt3b1 C657A, completely lost the ability to interact
with both the Dnmt3b1 and Dnmt3b3 C-terminal GST
fusion constructs (this same mutation had no effect on
the Dnmt3b–Dnmt3L interaction). With the exception
of the ICF syndrome-associated V612A and R829G
mutations, all Dnmt3b1 point mutants interacted with
both the Dnmt3b1 and Dnmt3b3 C-terminal GST
fusions, suggesting that the majority of ICF mutations
do not disrupt this interaction (Figure 5 and Table 1).
Taken together, these results demonstrate that Dnmt3b
makes extensive interactions with itself and with other al-
ternatively spliced Dnmt3b isoforms and that most ICF
syndrome-associated Dnmt3b mutations do not impair
Figure 5. Impact of alternative splicing, domain deletions and ICF syndrome-associated mutations on Dnmt3b1 interaction with the catalytic
domains (CD) of Dnmt3b1 and Dnmt3b3. (A) Top panel: schematic of the GST-tagged catalytic domain of Dnmt3b1 used for protein–protein
interaction pull downs. Catalytic motifs are indicated by roman numerals. Numbering indicates amino acids of Dnmt3b present in the construct.
Bottom panel: representative western blots using anti-6XHis tag antibody to study protein–protein interactions between the indicated Dnmt30s and
GST-Dnmt3b1 CD.+, pull down with GST-Dnmt3b1 CD; ,pull down with GST (negative control), low and high refer to the 100 and 150mM KCl
used in binding reaction/washes, respectively. (B) Top panel: schematic of the Dnmt3b3 catalytic domain-GST fusion protein used for pull downs.
Numbering denotes amino acids of Dnmt3b present in the construct and the alternatively spliced region characteristic of Dnmt3b3. Bottom panel:
representative western blots using anti-6XHis tag antibody to detect protein–protein interactions between the indicated Dnmt3 constructs and
GST-Dnmt3b3 CD. (C) 6X-His fusion protein and (D) GST-fusion protein inputs used in the pull down reactions to demonstrate equal loading.
Reactions identical to the pull downs (without washing) were run with the pull down reactions and proteins detected by western blotting with
antibodies against the 6XHis or GST tags. Arrowhead—speciﬁc protein, asterisk—non-speciﬁc band.
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with ICF mutant Dnmt3b). Regions of both the N- and
C-terminus of Dnmt3b are important for self-interaction,
including the catalytic center. Surprisingly, Dnmt3b3,
which lacks a portion of the catalytic domain and might,
based on the Dnmt3a crystal structure data (29), be pre-
dicted not to self-interact, actually interacted more
robustly and promiscuously with all other Dnmt3b
isoforms and mutants, suggesting that this widely ex-
pressed but catalytically inactive isoform binds to and
perhaps modulates the activity of catalytically competent
Dnmt3a and Dnmt3b proteins in vivo in cells where they
are co-expressed.
Trimolecular Dnmt3 interactions: effects of Dnmt3b
isoforms and mutants on the activity of Dnmt3a–Dnmt3L
Given our previous data that Dnmt3b forms extensive
interactions with other Dnmt3b isoforms, Dnmt3a and
Dnmt3L, and others’ data that Dnmt3b in ES cells
exists in a complex with Dnmt3a and Dnmt3L (2,3), we
next asked how addition of all three Dnmt3s to the same
reaction would affect methylation activity. Although all
three proteins co-purify, the exact composition and stoi-
chiometry of this complex is unknown [e.g. a 3L–3a–3b–
3L complex or some other higher order complex inter-
action as suggested by recent scanning force microscopy
experiments (38)]. Therefore Dnmt3a, Dnmt3b1 and
Dnmt3L, in an equimolar ratio, were co-incubated with
the SAT2-containing plasmid and SAM for 7h. Digestion
of in vitro methylated DNA with HpaII followed by gel
quantitation revealed that a Dnmt3a–Dnmt3b1–Dnmt3L-
containing reaction had higher activity than either
Dnmt3a–Dnmt3L or Dnmt3b1–Dnmt3L bimolecular
reaction, however the total activity was essentially additive
(that is a sum of the Dnmt3b1+Dnmt3L and Dnmt3a+
Dnmt3L activities) rather than synergistic. Similar results
were obtained using pyrosequencing to assess methylation
levels at the SAT2 and plasmid regions (Figure 6,
Supplementary Figure S5 and Table 1). Activity of a
trimolecular reaction containing Dnmt3b2 also yielded ac-
tivity approximately equivalent to individual Dnmt3b2+
Dnmt3L and Dnmt3a+Dnmt3L reactions. Addition of
proteins in different sequences with preincubation (e.g.
Dnmt3b+Dnmt3L then add Dnmt3a) did not change
activity levels (data not shown).
Of particular interest, however, was the ﬁnding that mix-
ing catalytically inactive Dnmt3b isoforms (e.g. Dnmt3b1
C657A, Dnmt3b3 or inactive ICF mutants) ‘stimulated’
the activity of Dnmt3a and Dnmt3L in the reaction mix-
tures as much as catalytically competent Dnmt3b isoforms
(by  20–30%, Figure 6, Supplementary Figure S5 and
Table 1). This effect is clearly a stimulation of Dnmt3a–
Dnmt3L activity because our prior experiments showed
that these Dnmt3b isoforms/mutants had no enzymatic ac-
tivity in the absence or presence of Dnmt3L in multiple
independent assays. Additional experiments mixing other
inactive Dnmt3b isoforms (e.g. C657A) with Dnmt3b3, in
the absence of Dnmt3L, also showed no evidence for
Dnmt3b3 having enzymatic activity (data not shown).
Activity of Dnmt3a–Dnmt3L on the plasmid was
generally stimulated to a greater extent by Dnmt3b than
the Dnmt3a–Dnmt3L activity toward SAT2 (assessed by
pyrosequencing). The stimulation of Dnmt3a–Dnmt3L by
inactive Dnmt3b isoforms, while modest, was highly re-
producible. Dnmt3b isoforms generally increased methy-
lation at all CpG sites rather than targeting a few
speciﬁc sites for increase (Supplementary Figure S5). All
ICF syndrome-associated Dnmt3b point mutants, regard-
less of their activity in isolation or in combination with
Dnmt3L, stimulated Dnmt3a–Dnmt3L activity (Figure 6,
Supplementary Figure S5 and Table 1). Deletion of
the PWWP domain (amino acids 225–249) reduced
Dnmt3b1 stimulation and deletion of amino acids
227–429 reduced it further, suggesting an important role
for residues 250–429 in mediating this effect. Deletion of
Figure 6. Effects of Dnmt3b alternative splicing, deletions and ICF
syndrome-associated mutations on the enzymatic activity of Dnmt3a
combined with Dnmt3L. (A) Representative HpaII restriction digests
of SAT2-containing plasmid following methyltransferase activity assay
combining Dnmt3a and Dnmt3L with the indicated Dnmt3b proteins.
Lanes 8 (no Dnmt3) and 9 (no SAM) are negative controls. (B) Effects
of select Dnmt3b constructs on methylation of the SAT2 sequence
when mixed with Dnmt3a+Dnmt3L relative to Dnmt3a+Dnmt3L
alone. Percent methylation is quantitated by HpaII digestion (black
bars) and pyrosequencing at both the SAT2 and plasmid regions
(light and dark gray bars, respectively), relative to a reaction with
only Dnmt3a+Dnmt3L. Active 3b: +, construct has demonstrated
activity alone; –, construct does not possess catalytic activity alone.
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Dnmt3b1 also abolished the stimulatory effect on
Dnmt3a–Dnmt3L (Supplementary Figures S5B and E,
Table 1). The ability of some Dnmt3b1 deletions/splice
variants, but not others, to stimulate Dnmt3a–Dnmt3L
activity argues against this effect being due to non-speciﬁc
protein–protein interactions or buffer effects. Deletion of
these same regions also impairs Dnmt3b1 self-interactions
(Table 1). Although at present we do not know the exact
composition of the complexes or interactions that occur in
the Dnmt3b–Dnmt3a–Dnmt3L-containing reactions, our
data suggest that Dnmt3b is capable of modulating the
activity of Dnmt3a–Dnmt3L complexes independent of
its catalytic activity via residues within both the N- and
C-terminal domains. Our data are consistent with an
in vivo study showing that a catalytically inactive
Dnmt3a point mutant stimulated Dnmt3b methylation
of the Oct4 promoter in ES cells, which also express
high levels of Dnmt3b (3).
In vivo versus in vitro SAT2 DNA methylation patterns
and Dnmt3b/Dnmt3L cellular localization
Our data thus far is derived entirely from in vitro studies
and as such lacks the information provided to Dnmt3b by
chromatin structure and the histone code. To begin to
extend the relevance our ﬁndings to the in vivo regulation
of DNA methylation, we compared patterns of SAT2
methylation derived from the in vitro studies here, with
our previous analysis of SAT2 DNA methylation
patterns in the HCT116 colorectal cancer cell line gen-
erated by traditional BGS (18,24). This analysis revealed
that CpG sites preferred by Dnmt3b in vitro are also
preferred sites of methylation in vivo (Supplementary
Figure S6). In vitro Dnmt3a SAT2 methylation patterns,
in contrast, showed no correlation with SAT2 methylation
patterns in HCT116 cells.
We next examined the cellular localization of Dnmt3b1,
Dnmt3b2 and Dnmt3b3 alone and with Dnmt3L by fusing
the open reading frame of each to green or red ﬂuorescent
proteins (GFP/RFP), transfecting the plasmids into
human HEK293T cells, and visualizing each Dnmt using
confocal microscopy. Dnmt3b1 and Dnmt3b3 displayed
exclusively nuclear staining with enrichment in ‘DAPI’-
dense regions of heterochromatin (Dnmt3b1 enrichment
in these regions was greater than Dnmt3b3, representa-
tive images are shown in Figure 7A). While the nuclear
staining of Dnmt3b2 was similar to that of Dnmt3b1/3b3,
almost 50% of cells displayed some cytoplasmic staining
(Figure 7A, compare two cells in Dnmt3b2 panel).
Dnmt3L was equally distributed throughout the nucleus
and cytoplasm. The majority of each Dnmt3b colocal-
ized with nuclear Dnmt3L upon co-transfection. Fewer
cells displayed cytoplasmic localization of Dnmt3b2
and Dnmt3L was more concentrated in the nucleus in
co-transfected cells (Figure 7B). Similar results were ob-
tained when Dnmt3b2 and Dnmt3b3 were co-transfected
with Dnmt3b1 (Figure 7C). We also examined localization
of the Dnmt3b1 C657A mutant (showing normal Dnmt3L
but abolished Dnmt3b1/3b3 interaction in vitro), the
Dnmt3b1 227–429, and the Dnmt3b1 V612A ICF
mutants (both displayed weakened Dnmt3L/Dnmt3b
interaction in vitro, Table 1) alone and with Dnmt3b1.
293T cells singly transfected with Dnmt3b1 C657A or
Dnmt3b1 V612A displayed localization patterns very
similar to WT Dnmt3b1 (although the Dnmt3b1 C657A
foci were larger), while the Dnmt3b1 227–429 mutant
was distinct; localizing predominantly to the cytoplasm
(diffuse and focal concentrations, Figure 7D). These
patterns changed little when Dnmt3b1 C657A or
Dnmt3b1 V612A were co-transfected with Dnmt3b1, but
a fraction of the Dnmt3b1 227–429 mutant became
nuclear when co-transfected with Dnmt3b1 (Figure 7E),
supporting our in vitro data that while the Dnmt3b1
227–429—Dnmt3b1 interaction is weakened (Table 1),
they are still capable of interacting. Taken together, these
results show that some isoforms/mutants of Dnmt3b dis-
playing altered properties in vitro also show distinctive
localization patterns in vivo. These data also illustrate
that other factors are likely inﬂuencing Dnmt3b localiza-
tion in vivo, such as chromatin and the presence of en-
dogenous wild-type Dnmt3b and Dnmt3a. As such,
while in vitro studies are capable of revealing novel func-
tional properties of Dnmt3b because they allow for
rigorous control over its environment, future in vivo
studies will also be essential for fully understanding how
speciﬁc domains and protein–protein interactions regulate
Dnmt3b’s function.
DISCUSSION
In the present study, we examined the consequences of
alternative splicing, deletion of speciﬁc domains and
disease-associated point mutations on the ability of
Dnmt3b to bind a native target DNA sequence (SAT2),
to interact with itself, Dnmt3a and Dnmt3L, and to
methylate several different DNA substrates using a com-
prehensive panel of in vitro assays. Our data reveal several
important and novel ﬁndings. First, naturally occurring
(Dnmt3b2) and ubiquitously expressed (Dnmt3b3) splice
variants resulted in Dnmt3b proteins with reduced DNA
binding afﬁnity and altered ability to interact with itself
and Dnmt3L. These isoforms had little effect on Dnmt3b’s
interaction with Dnmt3a and did not alter CpG site
preferences (for Dnmt3b2). Second, all ICF syndrome-
associated Dnmt3b mutants, in the context of the full-
length protein, resulted in decreased DNA binding
afﬁnity and all, except the G669S mutant, displayed
decreased binding afﬁnity for Dnmt3L. The Dnmt3b
L670T, V732G, A772P and H820R mutants were catalyt-
ically inactive. Dnmt3b R829G and R846Q mutants
retained activity, which was enhanced by Dnmt3L, even
though these mutations reduced both DNA binding
afﬁnity and Dnmt3L interaction. Similar to our ﬁndings
using the domain deletions and splice variants, none of the
ICF syndrome Dnmt3b mutations altered CpG site pref-
erence or impaired Dnmt3b self-interactions. Third, while
the Dnmt3b3 isoform was catalytically inactive; unexpect-
edly, it was able to interact with all other Dnmt3b
isoforms, domain deletions, ICF syndrome mutants and
Dnmt3a as well as, and in most cases better, than the
Nucleic Acids Research, 2011,Vol.39, No. 12 4997Figure 7. Localization of Dnmt3b isoforms/mutations and Dnmt3L in transiently transfected HEK 293T cells. (A) Representative cells showing local-
ization of indicated GFP-tagged Dnmt3b splice variants and DsRed-tagged Dnmt3L when transfected alone. (B) Representative cells
showing colocalization of GFP-tagged Dnmt3b splice variants with DsRed-tagged Dnmt3L when cotransfected. (C) Representative cells showing
colocalization of GFP-tagged Dnmt3b splice variants with DsRed-tagged Dnmt3b1when cotransfected. (D) Localization of GFP-tagged Dnmt3b1
C657A catalytic mutant, Dnmt3b1 V612A ICF syndrome mutant, and the Dnmt3b1 227–429 deletion construct when transfected alone. Two
patterns representative of the population of transfected cells are shown for the 227–429 construct. (E) Representative cells showing colocalization of
GFP-tagged Dnmt3b1 C657A catalytic mutant, Dnmt3b1 V612A ICF syndrome mutant, and Dnmt3b1 227–429 co-transfected with DsRed-tagged
Dnmt3b1.
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Dnmt3b isoforms or mutants stimulated Dnmt3a–
Dnmt3L complex activity and active Dnmt3b isoforms
did not synergize with Dnmt3a–Dnmt3L under our
in vitro conditions. Fifth, although DNA binding, activity
and interaction with Dnmt3L have been previously linked
to the C-terminal catalytic domain of Dnmt3b, our studies
using full-length isoforms clearly show that the isolated
C-terminal domain is impaired in most of these functions
relative to full-length protein and that the N-terminal
domain makes important contributions to these proper-
ties. Finally, microscopic examination of cells transfected
with ﬂuorescent Dnmt3 constructs support the in vitro
data that splicing/mutations impact on in vivo functions,
but also show that other factors, such as chromatin struc-
ture, likely play a role. Taken together, these data reveal
novel modulatory functions for the N-terminal domain
of Dnmt3b and that catalytically inactive isoforms of
Dnmt3b are able to modulate the activity of Dnmt3a–
Dnmt3L complexes by an as yet unknown mechanism.
An interesting question that arises out of this work, and
the work of others (15,16,18,21), is why most cell types
possess the capacity to express so many Dnmt3b splice
variants. Furthermore, why are many of these co-
expressed in the same cell? There is clear evidence that
some alternatively spliced isoforms of Dnmt3b possess
altered functions. For example, the widely expressed
Dnmt3b3 isoform is catalytically inactive (Table 1).
Other consequences of alternative splicing include
altered ability to interact with other proteins. Our work
here clearly shows that these latter two possibilities do in
fact occur with the Dnmt3b2 and Dnmt3b3 splice
variants. Furthermore, in vivo, alternatively spliced
Dnmt3b isoforms may be targeted to different regions of
chromatin based on altered protein–protein interactions
or changes in the pattern of histone marks that Dnmt3b
is recruited to or repelled from by exclusion of speciﬁc
regions, such as the PWWP domain that was recently
reported to bind H3K36 trimethylation [in the context
of Dnmt3a (39)]. Alternatively, Dnmt3b splice variants,
particularly those lacking catalytic activity, may function
as rheostats to ﬁne tune Dnmt3b activity by altering its
ability to interact with Dnmt3a and/or Dnmt3L, with
other interaction partner(s), or with particular chromatin
signatures in vivo. They may also change the properties of
Dnmt3a when complexed together. Catalytically inactive
DNMT3B4 and DNMT3B35, when overexpressed,
result in genomic hypomethylation, suggesting they
inhibit or compete for binding to the same DNA se-
quences as other active Dnmt3 isoforms (18,19). Inactive
Dnmt3b isoforms may stimulate active Dnmt3a/Dnmt3b
(with or without Dnmt3L)-containing complexes. This
notion is supported by our in vitro data and results
of others showing that overexpression of the DNMT3B7
splice variant results in both hypo- and hypermethylation
events in vivo (15,20) and that an inactive form of Dnmt3a
stimulated Dnmt3b methylation of the Oct4 promoter
in vivo (3). Dnmt3b splice variants could also titrate
Dnmt3a/Dnmt3L away from active isoforms of
Dnmt3b1; however, this may not necessarily be to
reduce activity as we have shown that inactive Dnmt3b
variants have the capacity, albeit limited, to stimulate the
activity of Dnmt3a/Dnmt3L complexes. Alternate splicing
may, therefore, represent one of the major mechanisms for
regulating overall Dnmt3b activity. Continued transcrip-
tion of the Dnmt3b gene with highly regulated alternative
splicing, rather than silencing of the locus, may permit
rapid changes in Dnmt3b activity, allowing it to respond
more quickly to stimuli.
The impact of Dnmt3L on Dnmt3a has been more ex-
tensively studied compared to Dnmt3b both in vitro and
in vivo. Dnmt3b is, in general, expressed earlier than
Dnmt3a during embryonic development and both are
expressed in a tissue-speciﬁc manner (5,40). Dnmt3L
expression coincides with Dnmt3a expression during de-
velopment of the testis while it coincides with Dnmt3b
expression in the ovary after birth (41). Interestingly,
germ cell-speciﬁc knockouts of Dnmt3a and Dnmt3L
yielded remarkably similar phenotypes—both largely af-
fecting methylation patterns at imprinted regions. In
contrast, pericentromeric repeats, established targets of
Dnmt3b, were not affected in any of the Dnmt3L
knockout mice (42–44). The nature and importance of
Dnmt3b–Dnmt3L interactions during development there-
fore remains uncertain. Our studies shed some new light
on the Dnmt3b–Dnmt3L interaction. Dnmt3L increased
the activity of all active Dnmt3b isoforms, deletions, and
three of the ICF syndrome mutants. Dnmt3L did not alter
Dnmt3b CpG sequence preference, but did enhance its
processivity. Dnmt3L also enhances the processivity of
Dnmt3a based on a recent study (34) suggesting that
this is a conserved function of Dnmt3L. Notably, CpGs
that had the lowest levels of methylation by Dnmt3b in the
absence of Dnmt3L, displayed the greatest increase in
methylation upon Dnmt3L addition. An identical effect
of Dnmt3L on Dnmt3a was also recently reported (45).
All of our Dnmt3b constructs, with the exception of the
671–859 mutant, interacted with Dnmt3L at the lower
salt concentration. Loss of Dnmt3b–Dnmt3L interaction
at the higher salt condition, interestingly, did not predict
loss of Dnmt3L stimulation of Dnmt3b in activity assays,
suggesting that a strong or extended interaction is un-
necessary for Dnmt3L to exert its effects. Another novel
observation from our work is that Dnmt3L enhanced the
DNA binding afﬁnity of DNMT3B1 on the SAT2 probe.
A prior study reported that Dnmt3L did not bind DNA
on its own (46), consistent with our ﬁndings. This same
study also showed that Dnmt3L increased Dnmt3b
mobility in a gel shift assay suggesting that Dnmt3L dis-
sociates Dnmt3b1 aggregates, exposing the catalytic
domain to the DNA and enhancing activity (46).
Dnmt3L may alter the conformation of the DNA
binding region of Dnmt3b in a way that enhances its
afﬁnity for DNA. In addition, our data show that the
N-terminal domain of Dnmt3b, while not essential, does
inﬂuence Dnmt3b’s ability to bind Dnmt3L in the context
of the full-length protein. Dnmt3b sequences, including
and in particular C-terminally ﬂanking the PWWP
domain, were also important for Dnmt3b–Dnmt3b inter-
actions. The PWWP domain of Dnmt3a contains an
allosteric DNA binding site that alters Dnmt3a cata-
lytic activity and self-interaction (aggregation) (47),
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ﬂanking sequences are important for several of
Dnmt3b’s properties.
An unexpected ﬁnding based on our in vitro pull down
experimentswasthattheDnmt3b3isoforminteractedmore
strongly and more promiscuously with almost all other
Dnmt3b isoforms/deletions/mutations and Dnmt3a. Only
the interaction between Dnmt3b3 and Dnmt3L appeared
somewhat weaker than the Dnmt3b1–Dnmt3L interaction.
Most of the ICF syndrome Dnmt3b mutants also fol-
lowed this trend, except for the L670T mutation (present
in the Dnmt3b–Dnmt3L interface/active site loop region
based on the Dnmt3a–Dnmt3L structure) and the A772P
mutation (proposed to inﬂuence Dnmt3a stability) (29),
which interacted with the Dnmt3b1 and Dnmt3b3
C-termini equally well (Table 1). This study postulated
that the H814R, D817G and V818M DNMT3B ICF
syndrome mutation were located in the Dnmt3b–Dnmt3b
interface and would be unable to self-interact (29).
Although, we have not examined all possible ICF
syndrome mutations here, mutation of nearby residues
(H820R and R829G) clearly impacted Dnmt3b self-
interactions involving Dnmt3b1 but had far less impact
on interactions involving Dnmt3b3. Ueda et al. (48) also
analyzed some of the same mutations and reported that
the L670T, V732G, A772P and D823G Dnmt3b muta-
tions did not disrupt Dnmt3a–Dnmt3b interaction using
co-immunoprecipitation assays, but the A609T ICF
mutation did abolish interaction. The V612A and R829G
mutations we analyzed were unable to interact with
Dnmt3b1 based on our pull down assays. The Dnmt3a–
Dnmt3L structural studies (29) collectively suggested that
exclusion of exons 22 and 23 (in murine Dnmt3b3) would
eliminate Dnmt3b self-interactions. Our data do not
support this notion, suggesting that Dnmt3b interacts
with itself differently than Dnmt3a and/or that the
Dnmt3b N-terminus (which also mediates self-interaction)
is compensating for mutations in the C-terminal domain.
Interestingly, an alternatively spliced isoform of Dnmt3a
resembling Dnmt3b3 has not, to our knowledge, been
identiﬁed suggesting that there may be important differ-
ences in the way Dnmt3a and Dnmt3b interact with them-
selves, and possibly also with Dnmt3L. The lack of
C-terminal exons 22 and 23 might cause Dnmt3b3 to
adopt a more open structure compared to the catalytically
active Dnmt3b1 isoform, permitting greater ﬂexibility in
what it interacts with.
We believe that our ﬁndings, based on in vitro data,
have potential relevance to the DNA methylation changes
that occur in transformed cells. Tumor cells exhibit both
hypo- and hypermethylation defects (7). While a mechan-
ism such as elevated DNMT expression could explain
the hypermethylation events, it does little to account for
genomic hypomethylation. Improper expression of normal
Dnmt3b splice variants [such as DNMT3B4 (19)] in the
wrong cell type or de novo expression of aberrant tran-
scripts during tumorigenesis [such as DNMT3B7 (20)]
represents an attractive alternative mechanism able to
account for both types of methylation defects that occur
in cancer cells. Our data, and that of others (20), show that
full-length Dnmt3b isoforms interact with other mutant
forms of Dnmt3b that contain only the N-terminal regu-
latory domain. Our Dnmt3b1 584–859 mutant interacts
with the full-length Dnmt3b3 isoform and DNMT3B7
(containing the ﬁrst 360 amino acids of DNMT3B1)
co-immunoprecipitates with other DNMT3B isoforms
(20). Interestingly, both of these isoforms lack the
Dnmt3b–Dnmt3b interface predicted from structural
studies (29). Furthermore, our EMSA data revealed the
presence of a strong DNA binding domain in the context
of the ﬁrst 433 amino acids of Dnmt3b1. These ﬁndings
may have relevance in tumor cells that express
C-terminally truncated forms of Dnmt3b because they
suggest that the truncated form interacts with other
‘normal’ Dnmt3b isoforms. Such an interaction could
alter the activity, DNA binding, or Dnmt3a/Dnmt3L
interaction of normal Dnmt3b isoforms. In addition,
because of the strong afﬁnity for DNA of N-terminal
Dnmt3b fragments, they may out-compete normal
Dnmt3b isoforms with their lower DNA binding afﬁnity
or recruit active Dnmt3b isoforms to sequences not
normally targeted by Dnmt3b. Any of these scenarios
could result in loss of Dnmt3b-mediated DNA methyla-
tion at normal targets and promote de novo methylation
at abnormal targets in vivo. As such, further character-
ization of the functional consequences of Dnmt3b alter-
native splicing may provide important insights into
the molecular underpinnings of tumor-associated global
DNA methylation defects.
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